New clinical trial at UTHealth Houston tests gene therapy vector that delivers drug aimed at stopping overactive bladder in patients with spinal cord injury
A modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder in people with spinal cord injury is underway in a first-in-human clinical trial by UTHealth Houston at TIRR Memorial Hermann.